WEC
VRTX icon

Winslow Evans & Crocker’s Vertex Pharmaceuticals VRTX Stock Holding History

Winslow Evans & Crocker’s Portfolio VRTX Stock Details VRTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q4 		$67K Buy
282
+114
+68% +$26.2K 0.01% 529
2020
Q3 		$46K Sell
168
-2,255
-93% -$622K 0.01% 477
2020
Q2 		$703K Buy
+2,423
New +$657K 0.19% 113
2017
Q1 		– Sell
-128
Closed -$9.43K – 1282
2016
Q4 		$9.43K Sell
128
-38
-23% -$3.09K ﹤0.01% 894
2016
Q3 		$14.4K Hold
166
– – ﹤0.01% 814
2016
Q2 		$14.2K Buy
166
+1
+0.6% +$86 ﹤0.01% 791
2016
Q1 		$13.1K Sell
165
-1
-0.6% -$90 ﹤0.01% 811
2015
Q4 		$20.8K Hold
166
– – 0.01% 737
2015
Q3 		$17.2K Hold
166
– – 0.01% 761
2015
Q2 		$20.4K Hold
166
– – 0.01% 755
2015
Q1 		$19.5K Hold
166
– – 0.01% 737
2014
Q4 		$19.6K Sell
166
-74
-31% -$8.33K 0.01% 733
2014
Q3 		$27K Buy
240
+75
+45% +$7.14K 0.01% 682
2014
Q2 		$15.6K Sell
165
-70
-30% -$4.91K 0.01% 735
2014
Q1 		$16.6K Hold
235
– – 0.01% 714
2013
Q4 		$17K Buy
+235
New +$16.4K 0.01% 750

Other funds holding VRTX

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
AllianceBernstein
AllianceBernstein Nashville, Tennessee $309B AUM 23.92% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return
ClearBridge Investments
ClearBridge Investments New York $115B AUM 24.78% 1-Year Est. Return

Winslow Evans & Crocker's VRTX Position: Q4 2020 in Review

Winslow Evans & Crocker increased its Vertex Pharmaceuticals (VRTX) stake by 68% in Q4 2020, buying an estimated $26.2K and bringing the position to 282 shares worth $67K. The position accounts for 0.01% of the portfolio, ranked #529.

Winslow Evans & Crocker first reported a position in VRTX in Q4 2013 and has held it in 16 quarters since. The position peaked at $703K in Q2 2020. 970 funds tracked by Wall St. Rank hold VRTX as of Q4 2020.

  • Winslow Evans & Crocker held 282 shares of Vertex Pharmaceuticals worth $67K as of Q4 2020.
  • Winslow Evans & Crocker bought 114 Vertex Pharmaceuticals shares in Q4 2020, an estimated $26.2K.
  • Vertex Pharmaceuticals made up 0.01% of Winslow Evans & Crocker's portfolio in Q4 2020, its #529 holding.
  • Winslow Evans & Crocker first reported a position in Vertex Pharmaceuticals in Q4 2013 and has held it in 16 quarters since.
  • Winslow Evans & Crocker's Vertex Pharmaceuticals position peaked at $703K in Q2 2020.
  • 970 funds tracked by Wall St. Rank held Vertex Pharmaceuticals as of Q4 2020.

Based on Winslow Evans & Crocker's 13F filing for Q4 2020, filed 3 Feb 2021.